{"id":742064,"date":"2011-11-22T15:23:00","date_gmt":"2011-11-22T15:23:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/"},"modified":"2026-08-10T13:01:15","modified_gmt":"2026-08-10T17:01:15","slug":"merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/","title":{"rendered":"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae"},"content":{"rendered":"<p class=\"bwalignc\">       Settlements Covered by Previously Announced Third-Quarter 2010 Charge     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        announced it has reached a resolution with federal and state authorities        regarding a previously disclosed investigation concerning Vioxx. Merck        voluntarily withdrew Vioxx from the market in September 2004. The        company previously recorded a charge of $950 million in October 2010 in        anticipation of today&#8217;s agreements.     <\/p>\n<p>       Under civil settlement agreements signed with the United States and        individually with 43 states and the District of Columbia, Merck will pay        approximately two-thirds of the reserved charge to resolve civil        allegations related to Vioxx. As a result, the United States and the        participating states have released Merck from civil liability related to        the governments&#8217; allegations regarding the sale and marketing of Vioxx        in the United States. Previously disclosed litigation with seven states        remains outstanding.     <\/p>\n<p>       The civil settlement does not constitute any admission by Merck of any        liability or wrongdoing.     <\/p>\n<p>       &#8220;We believe that Merck acted responsibly and in good faith in connection        with the conduct at issue in these civil settlement agreements,        including activities concerning the safety profile of Vioxx,&#8221; said Bruce        N. Kuhlik, executive vice president and general counsel of Merck.     <\/p>\n<p>       Separately, the company agreed to plead guilty to a misdemeanor under        the Federal Food, Drug, and Cosmetic Act arising out of the marketing of        Vioxx by company&nbsp;representatives to physicians in the United States for        the treatment of rheumatoid arthritis before the FDA&#8217;s approval of that        indication in April 2002. The company will pay a fine of approximately        one-third of the reserved amount to the federal government as part of        the plea agreement.     <\/p>\n<p>       As part of the plea agreement, the United States acknowledged&nbsp;that there        was no basis for a finding of high-level management participation in the        violation. The government also recognized Merck&#8217;s full cooperation with        its investigation.     <\/p>\n<p>       Merck also has entered into a new corporate integrity agreement (CIA)        with the Office of Inspector General (OIG) of the U.S. Department of        Health and Human Services. This agreement replaces Merck&#8217;s current CIA        and builds upon the company&#8217;s existing comprehensive compliance program.        Merck\u2019s compliance program includes specific policies and procedures        governing the company&#8217;s interactions with healthcare professionals and        is designed to help prevent, detect and resolve potential violations of        company policy or law.     <\/p>\n<p>       &#8220;Merck recognizes the importance of robust compliance programs and is        committed to adhering to the law and to our fundamental values and        standards. We believe that the settlement of this lengthy investigation        is in the best interests of our stakeholders, and we look forward to        focusing on our mission to save and improve lives around the world,&#8221;        said Kuhlik.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=50082649&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=83c176b49d908eb2f74a4d42946ce65c\">www.merck.com<\/a>        and connect with us on Twitter, Facebook and YouTube.     <\/p>\n<p>       <b>Merck Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes &#8220;forward-looking statements&#8221; within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company&#8217;s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck&#8217;s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and healthcare legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck&#8217;s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck&#8217;s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the United States and internationally and the exposure to        litigation and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck&#8217;s 2010 Annual Report on Form 10-K and the company&#8217;s other        filings with the Securities and Exchange Commission (SEC) available at<b>        <\/b>the SEC&#8217;s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50082649&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=dea8c9c04ee3fa3e88350c5d48d6e7e6\">www.sec.gov<\/a>).     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media Contacts:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Investor        Contact:<br \/>Carol Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has reached a resolution with federal and state authorities regarding a previously disclosed investigation concerning Vioxx. Merck voluntarily withdrew Vioxx from the market in September 2004. The company previously recorded a charge of $950 million in October 2010 in anticipation of today&#8217;s agreements. Under civil settlement agreements signed with the United States and individually with 43 states and the District of Columbia, Merck will pay approximately two-thirds of the reserved charge to resolve civil allegations related to Vioxx. As a result, the United States and the participating states have released Merck from civil liability related to the governments&#8217; allegations regarding the sale and marketing of Vioxx in the United States. Previously disclosed litigation with seven states remains outstanding. The civil settlement does not constitute any admission by Merck of any liability or wrongdoing. &#8220;We<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742064","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has reached a resolution with federal and state authorities regarding a previously disclosed investigation concerning Vioxx. Merck voluntarily withdrew Vioxx from the market in September 2004. The company previously recorded a charge of $950 million in October 2010 in anticipation of today&#039;s agreements. Under civil settlement agreements signed with the United States and individually with 43 states and the District of Columbia, Merck will pay approximately two-thirds of the reserved charge to resolve civil allegations related to Vioxx. As a result, the United States and the participating states have released Merck from civil liability related to the governments&#039; allegations regarding the sale and marketing of Vioxx in the United States. Previously disclosed litigation with seven states remains outstanding. The civil settlement does not constitute any admission by Merck of any liability or wrongdoing. &quot;We\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\\\/\",\"name\":\"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-11-22T15:23:00+00:00\",\"dateModified\":\"2026-08-10T17:01:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/","og_locale":"en_US","og_type":"article","og_title":"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced it has reached a resolution with federal and state authorities regarding a previously disclosed investigation concerning Vioxx. Merck voluntarily withdrew Vioxx from the market in September 2004. The company previously recorded a charge of $950 million in October 2010 in anticipation of today's agreements. Under civil settlement agreements signed with the United States and individually with 43 states and the District of Columbia, Merck will pay approximately two-thirds of the reserved charge to resolve civil allegations related to Vioxx. As a result, the United States and the participating states have released Merck from civil liability related to the governments' allegations regarding the sale and marketing of Vioxx in the United States. Previously disclosed litigation with seven states remains outstanding. The civil settlement does not constitute any admission by Merck of any liability or wrongdoing. \"We","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:15+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/","name":"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-11-22T15:23:00+00:00","dateModified":"2026-08-10T17:01:15+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-attorneys-office-for-the-district-of-massachusetts-related-to-vioxx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Resolves Previously Disclosed Seven-Year Investigation Led by U.S. Attorney\u2019s Office for the District of Massachusetts Related to Vioxx\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"854bf5cc-4d64-4436-978d-1d594681ec98","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Resolves-Previously-Disclosed-Seven-Year-Investigation-Led-by-US-Attorneys-Office-for-the-District-of-Massachusetts-Related-to--P2IZ2.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742064\/revisions"}],"predecessor-version":[{"id":3679200,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742064\/revisions\/3679200"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742064"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}